每天一日三餐，很多人遵循着固定的饮食模式，日复一日。然而，如今许多健康问题，如高血糖、脂肪肝和肥胖，并非源于营养不足，而是由于营养过剩导致。日前一项实验研究揭示了一个惊人的发现：仅通过改变饮食习惯，坚持3个月，身体的生理年龄竟可年轻2.5岁！更令人欣 ...

Part 1 of the trial will assess single and multiple doses of ARO-INHBE monotherapy, while Part 2 of the study will assess ARO-INHBE in combination with tirzepatide. We anticipate results from Part 1 ...

which along with PNH and IgAN include atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathy (C3G), and idiopathic membranous nephropathy (IMN). IgAN is a key focus for Novartis ...

Piper Sandler adjusted its stance on Q32 Bio Inc. (NASDAQ: QTTB), downgrading the biotech firm's stock rating from Overweight to Neutral and significantly reducing the price target to $4.00 from the ...

Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 ...

Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...

Leerink Partnrs decreased their FY2025 earnings estimates for shares of Q32 Bio in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now ...

An FDA advisory committee panel is scheduled to discuss the merits of Novartis’ oral factor B inhibitor Fabhalta in the rare kidney disease C3 glomerulopathy (C3G). The Cardiovascular and Renal ...

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently ...

After hours: February 7 at 7:44:24 PM EST Loading Chart for OMER ...